高効能API（HPAPI）の世界市場レポート2020

• 英文タイトル：Global High Potency APIs (HPAPI) Sales Market Report 2020

• レポートコード：20QY06-05639 • 出版社/出版日：QYResearch / 2020年6月2日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、142ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品・医療

• 販売価格（消費税別）

Single User	￥592,000 (USD4,000)	▷ お問い合わせ
Multi User	￥888,000 (USD6,000)	▷ お問い合わせ
Enterprise License	￥1,184,000 (USD8,000)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社の当調査資料では、高効能API（HPAPI）のグローバル市場について種類別（革新的、ジェネリック）、用途別（腫瘍学、緑内障、ホルモン不均衡、呼吸器疾患、その他）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。 ・高効能API（HPAPI）市場の概要 ・世界の主要地域別高効能API（HPAPI）市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の高効能API（HPAPI）市場規模2015-2026：種類別（革新的、ジェネリック） ・世界の高効能API（HPAPI）市場規模2015-2026：用途別（腫瘍学、緑内障、ホルモン不均衡、呼吸器疾患、その他） ・高効能API（HPAPI）の北米市場規模2015-2020 ・高効能API（HPAPI）のヨーロッパ市場規模2015-2020 ・高効能API（HPAPI）の中国市場規模2015-2020 ・高効能API（HPAPI）の日本市場規模2015-2020 ・高効能API（HPAPI）の東南アジア市場規模2015-2020 ・高効能API（HPAPI）のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 （Pfizer (US)、Novartis (Switzerland)、Sanofi (France)、Roche (Switzerland)、Eli Lilly and Company (US)、Merck (US)、AbbVie (US)、Boehringer Ingelheim (Germany)、GlaxoSmithKline (UK)、RAG-Stiftung (Germany)、Bristol-Myers Squibb (US)、Teva (Israel)、Mylan (US)、AstraZeneca (UK)、Lonza (Swiss）、Ash Stevens (US)、AMRI (US)） ・高効能API（HPAPI）の製造コスト分析 ・販売チャネル、流通業者、顧客 ・高効能API（HPAPI）の市場動向・機会・課題 ・調査の結論

A recently published report by QY Research titled Global High Potency APIs (HPAPI) Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate data in a statistical manner. It examines the historic accomplishments and recent opportunities present in the global High Potency APIs (HPAPI) market. QY Research report focuses on the consumption, geography, by type, by application, and the competitive landscape. The 4000 version of the report mainly splits the data for each region to analyze the leading companies, applications, and product types.
QY Research aims to provide a complete knowledgeable report so that the readers will benefit from it. The report is properly examined and compiled by industry experts and will shed light on the key information that requires from the clients.
Report Overview:
HPAPI is a very effective pharmacological active ingredient.Their effects are highly specific, providing significant efficiencies even at low daily therapeutic doses.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the High Potency APIs (HPAPI) market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the High Potency APIs (HPAPI) industry.
Based on our recent survey, we have several different scenarios about the High Potency APIs (HPAPI) YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of High Potency APIs (HPAPI) will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
QY Research report provides an overview and scope of the global High Potency APIs (HPAPI) market, stating its drivers, trends, opportunities, and restraints. The report also comprises all key details of the global High Potency APIs (HPAPI) market such as market strategies, sales volumes, and consumption. The report also covers the names of all distribution channels such as manufacturers, suppliers, wholesalers, distributors, consumers, and dealers.
QY Research also presents the statistical data in the form of infographics, tables, and charts to predict the trends and developments of the global High Potency APIs (HPAPI) market over the forecast period. The research analysts have also used a framework such as key industry experts interview, research papers, refer journals, survey reports, and face-to-face interviews with expert professionals to know the detailed outlook of the global High Potency APIs (HPAPI) market. The report also includes nautical information, where it shows High Potency APIs (HPAPI) market product volume, utilization value, and production processes.
The research report also consists of a competitive landscape that describes the top players that are functioning in the global High Potency APIs (HPAPI) market. This report also describes the key developments and trends, mergers and acquisitions strategies, and new product innovation that will show an enormous benefit to the companies that are competing in the global High Potency APIs (HPAPI) market.
Geographical Analysis:
Based on region, the global High Potency APIs (HPAPI) market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players:
The major players that are operating in the global High Potency APIs (HPAPI) market are
Pfizer (US)
Novartis (Switzerland)
Sanofi (France)
Roche (Switzerland)
Eli Lilly and Company (US)
Merck (US)
AbbVie (US)
Boehringer Ingelheim (Germany)
GlaxoSmithKline (UK)
RAG-Stiftung (Germany)
Bristol-Myers Squibb (US)
Teva (Israel)
Mylan (US)
AstraZeneca (UK)
Lonza (Swiss）
Ash Stevens (US)
AMRI (US)
Segment by Type
Innovative
Generic
Segment by Application
Oncology
Glaucoma
Hormonal Imbalance
Respiratory Disorders
Other
Competitive Landscape:
Factors such as cost analysis, marketing strategy, factor analysis, distributors, sourcing strategy, and industrial chain are all the parts of the global High Potency APIs (HPAPI) market. The report also includes the analysis of the return on investment (ROI) feasibility with the estimated SWOT analysis.
The report covers the following objectives:
• Proliferation and maturation of trade in the global High Potency APIs (HPAPI) market.
• The market share of the global High Potency APIs (HPAPI) market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
• Current and future market trends that are influencing the growth opportunities and growth rate of the global High Potency APIs (HPAPI) market.
• Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global High Potency APIs (HPAPI) market.

レポート目次

---

1 High Potency APIs (HPAPI) Market Overview
1.1 High Potency APIs (HPAPI) Product Scope
1.2 High Potency APIs (HPAPI) Segment by Type
1.2.1 Global High Potency APIs (HPAPI) Sales by Type (2020-2026)
1.2.2 Innovative
1.2.3 Generic
1.3 High Potency APIs (HPAPI) Segment by Application
1.3.1 Global High Potency APIs (HPAPI) Sales Comparison by Application (2020-2026)
1.3.2 Oncology
1.3.3 Glaucoma
1.3.4 Hormonal Imbalance
1.3.5 Respiratory Disorders
1.3.6 Other
1.4 High Potency APIs (HPAPI) Market Estimates and Forecasts (2015-2026)
1.4.1 Global High Potency APIs (HPAPI) Sales Growth Rate (2015-2026)
1.4.2 Global High Potency APIs (HPAPI) Revenue and Growth Rate (2015-2026)
1.4.3 Global High Potency APIs (HPAPI) Price Trends (2015-2026)
1.5 Coronavirus Disease 2019 (Covid-19): High Potency APIs (HPAPI) Industry Impact
1.5.1 How the Covid-19 is Affecting the High Potency APIs (HPAPI) Industry
1.5.1.1 High Potency APIs (HPAPI) Business Impact Assessment – Covid-19
1.5.1.2 Supply Chain Challenges
1.5.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.5.2 Market Trends and High Potency APIs (HPAPI) Potential Opportunities in the COVID-19 Landscape
1.5.3 Measures / Proposal against Covid-19
1.5.3.1 Government Measures to Combat Covid-19 Impact
1.5.3.2 Proposal for High Potency APIs (HPAPI) Players to Combat Covid-19 Impact

2 High Potency APIs (HPAPI) Estimate and Forecast by Region
2.1 Global High Potency APIs (HPAPI) Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global High Potency APIs (HPAPI) Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global High Potency APIs (HPAPI) Sales Market Share by Region (2015-2020)
2.2.2 Global High Potency APIs (HPAPI) Revenue Market Share by Region (2015-2020)
2.3 Global High Potency APIs (HPAPI) Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global High Potency APIs (HPAPI) Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global High Potency APIs (HPAPI) Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States High Potency APIs (HPAPI) Estimates and Projections (2015-2026)
2.4.2 Europe High Potency APIs (HPAPI) Estimates and Projections (2015-2026)
2.4.3 China High Potency APIs (HPAPI) Estimates and Projections (2015-2026)
2.4.4 Japan High Potency APIs (HPAPI) Estimates and Projections (2015-2026)
2.4.5 Southeast Asia High Potency APIs (HPAPI) Estimates and Projections (2015-2026)
2.4.6 India High Potency APIs (HPAPI) Estimates and Projections (2015-2026)
3 Global High Potency APIs (HPAPI) Competition Landscape by Players
3.1 Global Top High Potency APIs (HPAPI) Players by Sales (2015-2020)
3.2 Global Top High Potency APIs (HPAPI) Players by Revenue (2015-2020)
3.3 Global High Potency APIs (HPAPI) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in High Potency APIs (HPAPI) as of 2019)
3.4 Global High Potency APIs (HPAPI) Average Price by Company (2015-2020)
3.5 Manufacturers High Potency APIs (HPAPI) Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key High Potency APIs (HPAPI) Players (Opinion Leaders)
4 Global High Potency APIs (HPAPI) Market Size by Type
4.1 Global High Potency APIs (HPAPI) Historic Market Review by Type (2015-2020)
4.1.1 Global High Potency APIs (HPAPI) Sales Market Share by Type (2015-2020)
4.1.2 Global High Potency APIs (HPAPI) Revenue Market Share by Type (2015-2020)
4.1.3 Global High Potency APIs (HPAPI) Price by Type (2014-2020)
4.2 Global High Potency APIs (HPAPI) Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global High Potency APIs (HPAPI) Sales Forecast by Type (2021-2026)
4.2.2 Global High Potency APIs (HPAPI) Revenue Forecast by Type (2021-2026)
4.2.3 Global High Potency APIs (HPAPI) Price Forecast by Type (2021-2026)
5 Global High Potency APIs (HPAPI) Market Size by Application
5.1 Global High Potency APIs (HPAPI) Historic Market Review by Application (2015-2020)
5.1.1 Global High Potency APIs (HPAPI) Sales Market Share by Application (2015-2020)
5.1.2 Global High Potency APIs (HPAPI) Revenue Market Share by Application (2015-2020)
5.1.3 Global High Potency APIs (HPAPI) Price by Application (2015-2020)
5.2 Global High Potency APIs (HPAPI) Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global High Potency APIs (HPAPI) Sales Forecast by Application (2021-2026)
5.2.2 Global High Potency APIs (HPAPI) Revenue Forecast by Application (2021-2026)
5.2.3 Global High Potency APIs (HPAPI) Price Forecast by Application (2021-2026)

3 North America High Potency APIs (HPAPI) Market Facts & Figures
3.2 North America High Potency APIs (HPAPI) Sales Market Share by Company (2015-2020)
3.3 North America High Potency APIs (HPAPI) Sales Market Share by Type (2015-2020)
3.4 North America High Potency APIs (HPAPI) Sales Market Share by Application (2015-2020)

4 Europe High Potency APIs (HPAPI) Market Facts & Figures
4.2 Europe High Potency APIs (HPAPI) Sales Market Share by Company (2015-2020)
4.3 Europe High Potency APIs (HPAPI) Sales Market Share by Type (2015-2020)
4.4 Europe High Potency APIs (HPAPI) Sales Market Share by Application (2015-2020)

5 China High Potency APIs (HPAPI) Market Facts & Figures
5.2 China High Potency APIs (HPAPI) Sales Market Share by Company (2015-2020)
5.3 China High Potency APIs (HPAPI) Sales Market Share by Type (2015-2020)
5.4 China High Potency APIs (HPAPI) Sales Market Share by Application (2015-2020)

6 Japan High Potency APIs (HPAPI) Market Facts & Figures
6.2 Japan High Potency APIs (HPAPI) Sales Market Share by Company (2015-2020)
6.3 Japan High Potency APIs (HPAPI) Sales Market Share by Type (2015-2020)
6.4 Japan High Potency APIs (HPAPI) Sales Market Share by Application (2015-2020)

7 Southeast Asia High Potency APIs (HPAPI) Market Facts & Figures
7.2 Southeast Asia High Potency APIs (HPAPI) Sales Market Share by Company (2015-2020)
7.3 Southeast Asia High Potency APIs (HPAPI) Sales Market Share by Type (2015-2020)
7.4 Southeast Asia High Potency APIs (HPAPI) Sales Market Share by Application (2015-2020)

8 India High Potency APIs (HPAPI) Market Facts & Figures
8.2 India High Potency APIs (HPAPI) Sales Market Share by Company (2015-2020)
8.3 India High Potency APIs (HPAPI) Sales Market Share by Type (2015-2020)
8.4 India High Potency APIs (HPAPI) Sales Market Share by Application (2015-2020)

12 Company Profiles and Key Figures in High Potency APIs (HPAPI) Business
12.1 Pfizer (US)
12.1.1 Pfizer (US) High Potency APIs (HPAPI) Corporation Information
12.1.2 Pfizer (US) High Potency APIs (HPAPI) Business Overview and Total Revenue
12.1.3 Pfizer (US) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Pfizer (US) High Potency APIs (HPAPI) Products Offered
12.1.5 Pfizer (US) Recent Development
12.2 Novartis (Switzerland)
12.2.1 Novartis (Switzerland) High Potency APIs (HPAPI) Corporation Information
12.2.2 Novartis (Switzerland) High Potency APIs (HPAPI) Business Overview and Total Revenue
12.2.3 Novartis (Switzerland) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Novartis (Switzerland) High Potency APIs (HPAPI) Products Offered
12.2.5 Novartis (Switzerland) Recent Development
12.3 Sanofi (France)
12.3.1 Sanofi (France) High Potency APIs (HPAPI) Corporation Information
12.3.2 Sanofi (France) High Potency APIs (HPAPI) Business Overview and Total Revenue
12.3.3 Sanofi (France) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Sanofi (France) High Potency APIs (HPAPI) Products Offered
12.3.5 Sanofi (France) Recent Development
12.4 Roche (Switzerland)
12.4.1 Roche (Switzerland) High Potency APIs (HPAPI) Corporation Information
12.4.2 Roche (Switzerland) High Potency APIs (HPAPI) Business Overview and Total Revenue
12.4.3 Roche (Switzerland) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Roche (Switzerland) High Potency APIs (HPAPI) Products Offered
12.4.5 Roche (Switzerland) Recent Development
12.5 Eli Lilly and Company (US)
12.5.1 Eli Lilly and Company (US) High Potency APIs (HPAPI) Corporation Information
12.5.2 Eli Lilly and Company (US) High Potency APIs (HPAPI) Business Overview and Total Revenue
12.5.3 Eli Lilly and Company (US) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Eli Lilly and Company (US) High Potency APIs (HPAPI) Products Offered
12.5.5 Eli Lilly and Company (US) Recent Development
12.6 Merck (US)
12.6.1 Merck (US) High Potency APIs (HPAPI) Corporation Information
12.6.2 Merck (US) High Potency APIs (HPAPI) Business Overview and Total Revenue
12.6.3 Merck (US) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Merck (US) High Potency APIs (HPAPI) Products Offered
12.6.5 Merck (US) Recent Development
12.7 AbbVie (US)
12.7.1 AbbVie (US) High Potency APIs (HPAPI) Corporation Information
12.7.2 AbbVie (US) High Potency APIs (HPAPI) Business Overview and Total Revenue
12.7.3 AbbVie (US) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2015-2020)
12.7.4 AbbVie (US) High Potency APIs (HPAPI) Products Offered
12.7.5 AbbVie (US) Recent Development
12.8 Boehringer Ingelheim (Germany)
12.8.1 Boehringer Ingelheim (Germany) High Potency APIs (HPAPI) Corporation Information
12.8.2 Boehringer Ingelheim (Germany) High Potency APIs (HPAPI) Business Overview and Total Revenue
12.8.3 Boehringer Ingelheim (Germany) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Boehringer Ingelheim (Germany) High Potency APIs (HPAPI) Products Offered
12.8.5 Boehringer Ingelheim (Germany) Recent Development
12.9 GlaxoSmithKline (UK)
12.9.1 GlaxoSmithKline (UK) High Potency APIs (HPAPI) Corporation Information
12.9.2 GlaxoSmithKline (UK) High Potency APIs (HPAPI) Business Overview and Total Revenue
12.9.3 GlaxoSmithKline (UK) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2015-2020)
12.9.4 GlaxoSmithKline (UK) High Potency APIs (HPAPI) Products Offered
12.9.5 GlaxoSmithKline (UK) Recent Development
12.10 RAG-Stiftung (Germany)
12.10.1 RAG-Stiftung (Germany) High Potency APIs (HPAPI) Corporation Information
12.10.2 RAG-Stiftung (Germany) High Potency APIs (HPAPI) Business Overview and Total Revenue
12.10.3 RAG-Stiftung (Germany) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2015-2020)
12.10.4 RAG-Stiftung (Germany) High Potency APIs (HPAPI) Products Offered
12.10.5 RAG-Stiftung (Germany) Recent Development
12.11 Bristol-Myers Squibb (US)
12.11.1 Bristol-Myers Squibb (US) High Potency APIs (HPAPI) Corporation Information
12.11.2 Bristol-Myers Squibb (US) High Potency APIs (HPAPI) Business Overview and Total Revenue
12.11.3 Bristol-Myers Squibb (US) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Bristol-Myers Squibb (US) High Potency APIs (HPAPI) Products Offered
12.11.5 Bristol-Myers Squibb (US) Recent Development
12.12 Teva (Israel)
12.12.1 Teva (Israel) High Potency APIs (HPAPI) Corporation Information
12.12.2 Teva (Israel) High Potency APIs (HPAPI) Business Overview and Total Revenue
12.12.3 Teva (Israel) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2015-2020)
12.12.4 Teva (Israel) High Potency APIs (HPAPI) Products Offered
12.12.5 Teva (Israel) Recent Development
12.13 Mylan (US)
12.13.1 Mylan (US) High Potency APIs (HPAPI) Corporation Information
12.13.2 Mylan (US) High Potency APIs (HPAPI) Business Overview and Total Revenue
12.13.3 Mylan (US) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2015-2020)
12.13.4 Mylan (US) High Potency APIs (HPAPI) Products Offered
12.13.5 Mylan (US) Recent Development
12.14 AstraZeneca (UK)
12.14.1 AstraZeneca (UK) High Potency APIs (HPAPI) Corporation Information
12.14.2 AstraZeneca (UK) High Potency APIs (HPAPI) Business Overview and Total Revenue
12.14.3 AstraZeneca (UK) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2015-2020)
12.14.4 AstraZeneca (UK) High Potency APIs (HPAPI) Products Offered
12.14.5 AstraZeneca (UK) Recent Development
12.15 Lonza (Swiss）
12.15.1 Lonza (Swiss） High Potency APIs (HPAPI) Corporation Information
12.15.2 Lonza (Swiss） High Potency APIs (HPAPI) Business Overview and Total Revenue
12.15.3 Lonza (Swiss） High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2015-2020)
12.15.4 Lonza (Swiss） High Potency APIs (HPAPI) Products Offered
12.15.5 Lonza (Swiss） Recent Development
12.16 Ash Stevens (US)
12.16.1 Ash Stevens (US) High Potency APIs (HPAPI) Corporation Information
12.16.2 Ash Stevens (US) High Potency APIs (HPAPI) Business Overview and Total Revenue
12.16.3 Ash Stevens (US) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2015-2020)
12.16.4 Ash Stevens (US) High Potency APIs (HPAPI) Products Offered
12.16.5 Ash Stevens (US) Recent Development
12.17 AMRI (US)
12.17.1 AMRI (US) High Potency APIs (HPAPI) Corporation Information
12.17.2 AMRI (US) High Potency APIs (HPAPI) Business Overview and Total Revenue
12.17.3 AMRI (US) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2015-2020)
12.17.4 AMRI (US) High Potency APIs (HPAPI) Products Offered
12.17.5 AMRI (US) Recent Development

13 High Potency APIs (HPAPI) Manufacturing Cost Analysis
13.1 High Potency APIs (HPAPI) Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of High Potency APIs (HPAPI)
13.4 High Potency APIs (HPAPI) Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 High Potency APIs (HPAPI) Distributors List
14.3 High Potency APIs (HPAPI) Customers

15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis

16 Research Findings and Conclusion

17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

List of Tables
Table 1. Global High Potency APIs (HPAPI) Sales (KG) Growth Rate by Type (2020-2026)
Table 2. Global High Potency APIs (HPAPI) Sales (KG) Comparison by Application (2020-2026)
Table 3. COVID-19 Impact Global Market: (Four High Potency APIs (HPAPI) Market Size Forecast Scenarios)
Table 4. Opportunities and Trends for High Potency APIs (HPAPI) Players in the COVID-19 Landscape
Table 5. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 6. Key Regions/Countries Measures against Covid-19 Impact
Table 7. Proposal for High Potency APIs (HPAPI) Players to Combat Covid-19 Impact
Table 8. Global Market High Potency APIs (HPAPI) Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 9. Global High Potency APIs (HPAPI) Sales (KG) by Region (2015-2020)
Table 10. Global High Potency APIs (HPAPI) Sales Market Share by Region (2015-2020)
Table 11. Global High Potency APIs (HPAPI) Revenue (US$ Million) Market Share by Region (2015-2020))
Table 12. Global High Potency APIs (HPAPI) Revenue Share by Region (2015-2020)
Table 13. Global High Potency APIs (HPAPI) Sales (KG) Forecast by Region (2021-2026)
Table 14. Global High Potency APIs (HPAPI) Sales Market Share Forecast by Region (2021-2026)
Table 15. Global High Potency APIs (HPAPI) Revenue (US$ Million) Forecast by Region (2021-2026)
Table 16. Global High Potency APIs (HPAPI) Revenue Share Forecast by Region (2021-2026)
Table 17. Global High Potency APIs (HPAPI) (KG) of Key Companies (2015-2020)
Table 18. Global High Potency APIs (HPAPI) Sales Share by Company (2015-2020)
Table 19. Global High Potency APIs (HPAPI) Revenue (US$ Million) by Company (2015-2020)
Table 20. Global High Potency APIs (HPAPI) Revenue Share by Company (2015-2020)
Table 21. Global High Potency APIs (HPAPI) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in High Potency APIs (HPAPI) as of 2019)
Table 22. Global High Potency APIs (HPAPI) Average Price (USD/KG) of Key Company (2015-2020)
Table 23. Manufacturers High Potency APIs (HPAPI) Manufacturing Sites and Area Served
Table 24. Manufacturers High Potency APIs (HPAPI) Product Type
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Main Points Interviewed from Key High Potency APIs (HPAPI) Players
Table 27. Global High Potency APIs (HPAPI) Sales (KG) by Type (2015-2020)
Table 28. Global High Potency APIs (HPAPI) Sales Share by Type (2015-2020)
Table 29. Global High Potency APIs (HPAPI) Revenue (US$ Million) Market Share by Type (2015-2020)
Table 30. Global High Potency APIs (HPAPI) Price (KG) by Type (2015-2020)
Table 31. Global High Potency APIs (HPAPI) Sales Share by Type (2021-2026)
Table 32. Global High Potency APIs (HPAPI) Revenue (US$ Million) Market Share by Type (2021-2026)
Table 33. Global High Potency APIs (HPAPI) Revenue Share by Type (2021-2026)
Table 34. Global High Potency APIs (HPAPI) Price (KG) by Type (2021-2026)
Table 35. Global High Potency APIs (HPAPI) Sales (KG) by Application (2015-2020)
Table 36. Global High Potency APIs (HPAPI) Sales Share by Application (2015-2020)
Table 37. Global High Potency APIs (HPAPI) Revenue (US$ Million) Market Share by Application (2015-2020)
Table 38. Global High Potency APIs (HPAPI) Price (KG) by Application (2015-2020)
Table 39. Global High Potency APIs (HPAPI) Sales (KG) by Application (2021-2026)
Table 40. Global High Potency APIs (HPAPI) Sales Share by Application (2021-2026)
Table 41. Global High Potency APIs (HPAPI) Revenue (US$ Million) Market Share by Application (2021-2026)
Table 42. Global High Potency APIs (HPAPI) Revenue Share by Application (2021-2026)
Table 43. Global High Potency APIs (HPAPI) Price (KG) by Application (2021-2026)
Table 44. United States High Potency APIs (HPAPI) Sales (KG) by Company (2015-2020)
Table 45. United States High Potency APIs (HPAPI) Sales Market Share by Company (2015-2020)
Table 46. United States High Potency APIs (HPAPI) Sales (KG) by Type (2015-2020)
Table 47. United States High Potency APIs (HPAPI) Sales Market Share by Type (2015-2020)
Table 48. United States High Potency APIs (HPAPI) Sales (KG) by Application (2015-2020)
Table 49. United States High Potency APIs (HPAPI) Sales Market Share by Application (2015-2020)
Table 50. Europe High Potency APIs (HPAPI) Sales (KG) by Company (2015-2020)
Table 51. Europe High Potency APIs (HPAPI) Sales Market Share by Company (2015-2020)
Table 52. Europe High Potency APIs (HPAPI) Sales (KG) by Type (2015-2020)
Table 53. Europe High Potency APIs (HPAPI) Sales Market Share by Type (2015-2020)
Table 54. Europe High Potency APIs (HPAPI) Sales (KG) by Application (2015-2020)
Table 55. Europe High Potency APIs (HPAPI) Sales Market Share by Type (2015-2020)
Table 56. China High Potency APIs (HPAPI) Sales (KG) by Company (2015-2020)
Table 57. China High Potency APIs (HPAPI) Sales Market Share by Company (2015-2020)
Table 58. China High Potency APIs (HPAPI) Sales (KG) by Type (2015-2020)
Table 59. China High Potency APIs (HPAPI) Sales Market Share by Type (2015-2020)
Table 60. China High Potency APIs (HPAPI) Sales (KG) by Application (2015-2020)
Table 61. China High Potency APIs (HPAPI) Sales Market Share by Application (2015-2020)
Table 62. Japan High Potency APIs (HPAPI) Sales (KG) by Company (2015-2020)
Table 63. Japan High Potency APIs (HPAPI) Sales Market Share by Company (2015-2020)
Table 64. Japan High Potency APIs (HPAPI) Sales (KG) by Type (2015-2020)
Table 65. Japan High Potency APIs (HPAPI) Sales Market Share by Type (2015-2020)
Table 66. Japan High Potency APIs (HPAPI) Sales (KG) by Application (2015-2020)
Table 67. Japan High Potency APIs (HPAPI) Sales Market Share by Application (2015-2020)
Table 68. Southeast Asia High Potency APIs (HPAPI) Sales (KG) by Company (2015-2020)
Table 69. Southeast Asia High Potency APIs (HPAPI) Sales Market Share by Company (2015-2020)
Table 70. Southeast Asia High Potency APIs (HPAPI) Sales (KG) by Type (2015-2020)
Table 71. Southeast Asia High Potency APIs (HPAPI) Sales Market Share by Type (2015-2020)
Table 72. Southeast Asia High Potency APIs (HPAPI) Sales (KG) by Type (2015-2020)
Table 73. Southeast Asia High Potency APIs (HPAPI) Sales Market Share by Application (2015-2020)
Table 74. India High Potency APIs (HPAPI) Sales (KG) by Company (2015-2020)
Table 75. India High Potency APIs (HPAPI) Sales Market Share by Company (2015-2020)
Table 76. India High Potency APIs (HPAPI) Sales (KG) by Type (2015-2020)
Table 77. India High Potency APIs (HPAPI) Sales Market Share by Type (2015-2020)
Table 78. India High Potency APIs (HPAPI) Sales (KG) by Application (2015-2020)
Table 79. India High Potency APIs (HPAPI) Sales Market Share by Application (2015-2020)
Table 80. Pfizer (US) Corporation Information
Table 81. Pfizer (US) Description and Business Overview
Table 82. Pfizer (US) High Potency APIs (HPAPI) Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 83. Pfizer (US) High Potency APIs (HPAPI) Product
Table 84. Pfizer (US) Recent Development
Table 85. Novartis (Switzerland) Corporation Information
Table 86. Novartis (Switzerland) Description and Business Overview
Table 87. Novartis (Switzerland) High Potency APIs (HPAPI) Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 88. Novartis (Switzerland) High Potency APIs (HPAPI) Product
Table 89. Novartis (Switzerland) Recent Development
Table 90. Sanofi (France) Corporation Information
Table 91. Sanofi (France) Description and Business Overview
Table 92. Sanofi (France) High Potency APIs (HPAPI) Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 93. Sanofi (France) High Potency APIs (HPAPI) Product
Table 94. Sanofi (France) Recent Development
Table 95. Roche (Switzerland) Corporation Information
Table 96. Roche (Switzerland) Description and Business Overview
Table 97. Roche (Switzerland) High Potency APIs (HPAPI) Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 98. Roche (Switzerland) High Potency APIs (HPAPI) Product
Table 99. Roche (Switzerland) Recent Development
Table 100. Eli Lilly and Company (US) Corporation Information
Table 101. Eli Lilly and Company (US) Description and Business Overview
Table 102. Eli Lilly and Company (US) High Potency APIs (HPAPI) Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 103. Eli Lilly and Company (US) High Potency APIs (HPAPI) Product
Table 104. Eli Lilly and Company (US) Recent Development
Table 105. Merck (US) Corporation Information
Table 106. Merck (US) Description and Business Overview
Table 107. Merck (US) High Potency APIs (HPAPI) Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 108. Merck (US) High Potency APIs (HPAPI) Product
Table 109. Merck (US) Recent Development
Table 110. AbbVie (US) Corporation Information
Table 111. AbbVie (US) Description and Business Overview
Table 112. AbbVie (US) High Potency APIs (HPAPI) Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 113. AbbVie (US) High Potency APIs (HPAPI) Product
Table 114. AbbVie (US) Recent Development
Table 115. Boehringer Ingelheim (Germany) Corporation Information
Table 116. Boehringer Ingelheim (Germany) High Potency APIs (HPAPI) Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 117. Boehringer Ingelheim (Germany) Description and Business Overview
Table 118. Boehringer Ingelheim (Germany) High Potency APIs (HPAPI) Product
Table 119. Boehringer Ingelheim (Germany) Recent Development
Table 120. GlaxoSmithKline (UK) Corporation Information
Table 121. GlaxoSmithKline (UK) High Potency APIs (HPAPI) Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 122. GlaxoSmithKline (UK) Description and Business Overview
Table 123. GlaxoSmithKline (UK) High Potency APIs (HPAPI) Product
Table 124. GlaxoSmithKline (UK) Recent Development
Table 125. RAG-Stiftung (Germany) Corporation Information
Table 126. RAG-Stiftung (Germany) Description and Business Overview
Table 127. RAG-Stiftung (Germany) High Potency APIs (HPAPI) Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 128. RAG-Stiftung (Germany) High Potency APIs (HPAPI) Product
Table 129. RAG-Stiftung (Germany) Recent Development
Table 130. Bristol-Myers Squibb (US) Corporation Information
Table 131. Bristol-Myers Squibb (US) Description and Business Overview
Table 132. Bristol-Myers Squibb (US) High Potency APIs (HPAPI) Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 133. Bristol-Myers Squibb (US) High Potency APIs (HPAPI) Product
Table 134. Bristol-Myers Squibb (US) Recent Development
Table 135. Teva (Israel) Corporation Information
Table 136. Teva (Israel) Description and Business Overview
Table 137. Teva (Israel) High Potency APIs (HPAPI) Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 138. Teva (Israel) High Potency APIs (HPAPI) Product
Table 139. Teva (Israel) Recent Development
Table 140. Mylan (US) Corporation Information
Table 141. Mylan (US) Description and Business Overview
Table 142. Mylan (US) High Potency APIs (HPAPI) Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 143. Mylan (US) High Potency APIs (HPAPI) Product
Table 144. Mylan (US) Recent Development
Table 145. AstraZeneca (UK) Corporation Information
Table 146. AstraZeneca (UK) Description and Business Overview
Table 147. AstraZeneca (UK) High Potency APIs (HPAPI) Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 148. AstraZeneca (UK) High Potency APIs (HPAPI) Product
Table 149. AstraZeneca (UK) Recent Development
Table 150. Lonza (Swiss） Corporation Information
Table 151. Lonza (Swiss） Description and Business Overview
Table 152. Lonza (Swiss） High Potency APIs (HPAPI) Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 153. Lonza (Swiss） High Potency APIs (HPAPI) Product
Table 154. Lonza (Swiss） Recent Development
Table 155. Ash Stevens (US) Corporation Information
Table 156. Ash Stevens (US) Description and Business Overview
Table 157. Ash Stevens (US) High Potency APIs (HPAPI) Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table 158. Ash Stevens (US) High Potency APIs (HPAPI) Product
Table 159. Ash Stevens (US) Recent Development
Table . AMRI (US) Corporation Information
Table . AMRI (US) Description and Business Overview
Table . AMRI (US) High Potency APIs (HPAPI) Sales (KG), Revenue (Million USD), Price (USD/KG) and Gross Margin (2015-2020)
Table . AMRI (US) High Potency APIs (HPAPI) Product
Table . AMRI (US) Recent Development
Table 165. Production Base and Market Concentration Rate of Raw Material
Table 166. Key Suppliers of Raw Materials
Table 167. High Potency APIs (HPAPI) Distributors List
Table 168. High Potency APIs (HPAPI) Customers List
Table 169. Market Key Trends
Table 170. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 171. Key Challenges
Table 172. Research Programs/Design for This Report
Table 173. Key Data Information from Secondary Sources
Table 174. Key Data Information from Primary Sources
List of Figures
Figure 1. High Potency APIs (HPAPI) Product Picture
Figure 2. Global High Potency APIs (HPAPI) Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global High Potency APIs (HPAPI) Market Share by Application in 2020 & 2026
Figure 6. Oncology Examples
Figure 7. Glaucoma Examples
Figure 8. Hormonal Imbalance Examples
Figure 9. Respiratory Disorders Examples
Figure 10. Other Examples
Figure 11. Global High Potency APIs (HPAPI) Sales (KG) Growth Rate (2015-2026)
Figure 12. Global High Potency APIs (HPAPI) Revenue (US$ Million) Growth Rate (2015-2026)
Figure 13. Global High Potency APIs (HPAPI) Price Trends Growth Rate (2015-2026) (USD/KG)
Figure 14. Global High Potency APIs (HPAPI) Revenue Market Share by Region: 2015 VS 2020
Figure 15. Global High Potency APIs (HPAPI) Revenue Market Share by Region: 2021 VS 2026
Figure 16. United States High Potency APIs (HPAPI) Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. United States High Potency APIs (HPAPI) Sales (KG) Growth Rate (2015-2026)
Figure 18. Europe High Potency APIs (HPAPI) Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. Europe High Potency APIs (HPAPI) Sales (Million USD) Growth Rate (2015-2026)
Figure 20. China High Potency APIs (HPAPI) Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. China High Potency APIs (HPAPI) Sales (Million USD) and Growth Rate (2015-2026)
Figure 22. Japan High Potency APIs (HPAPI) Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Japan High Potency APIs (HPAPI) Sales (Million USD) Growth Rate (2015-2026)
Figure 24. Southeast Asia High Potency APIs (HPAPI) Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. Southeast Asia High Potency APIs (HPAPI) Sales (Million USD) Growth Rate (2015-2026)
Figure 26. India High Potency APIs (HPAPI) Revenue (Million USD) Growth Rate (2015-2026)
Figure 27. India High Potency APIs (HPAPI) Sales (Million USD) Growth Rate (2015-2026)
Figure 28. Global 5 Largest High Potency APIs (HPAPI) Players Market Share by Revenue in High Potency APIs (HPAPI) 2015 & 2019
Figure 29. High Potency APIs (HPAPI) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 30. Global High Potency APIs (HPAPI) Revenue Share by Type (2015-2020)
Figure 31. Global High Potency APIs (HPAPI) Revenue Growth Rate by Type in 2015 & 2019
Figure 32. Global High Potency APIs (HPAPI) Revenue Share by Application (2015-2020)
Figure 33. Global High Potency APIs (HPAPI) Revenue Growth Rate by Application in 2015 & 2019
Figure 34. United States High Potency APIs (HPAPI) Sales Market Share by Type in 2019
Figure 35. United States High Potency APIs (HPAPI) Sales Market Share by Type in 2019
Figure 36. Europe High Potency APIs (HPAPI) Sales Market Share by Company in 2019
Figure 37. Europe High Potency APIs (HPAPI) Sales Market Share by Type in 2019
Figure 38. Europe High Potency APIs (HPAPI) Sales Market Share by Application in 2019
Figure 39. China High Potency APIs (HPAPI) Sales Market Share by Company in 2019
Figure 40. China High Potency APIs (HPAPI) Sales Market Share by Type in 2019
Figure 41. China High Potency APIs (HPAPI) Sales Market Share by Application in 2019
Figure 42. Japan High Potency APIs (HPAPI) Sales Market Share by Company in 2019
Figure 43. Japan High Potency APIs (HPAPI) Sales Market Share by Type in 2019
Figure 44. Japan High Potency APIs (HPAPI) Sales Market Share by Application in 2019
Figure 45. Southeast Asia High Potency APIs (HPAPI) Sales Market Share by Company in 2019
Figure 46. Southeast Asia High Potency APIs (HPAPI) Sales Market Share by Type in 2019
Figure 47. Southeast Asia High Potency APIs (HPAPI) Sales Market Share by Application in 2019
Figure 48. India High Potency APIs (HPAPI) Sales Market Share by Company in 2019
Figure 49. India High Potency APIs (HPAPI) Sales Market Share by Type in 2019
Figure 50. India High Potency APIs (HPAPI) Sales Market Share by Application in 2019
Figure 51. Pfizer (US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Novartis (Switzerland) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Sanofi (France) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Roche (Switzerland) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Eli Lilly and Company (US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Merck (US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. AbbVie (US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Boehringer Ingelheim (Germany) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. GlaxoSmithKline (UK) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. RAG-Stiftung (Germany) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Bristol-Myers Squibb (US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Teva (Israel) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Mylan (US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 64. AstraZeneca (UK) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 65. Lonza (Swiss） Total Revenue (US$ Million): 2019 Compared with 2018
Figure 66. Ash Stevens (US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 67. AMRI (US) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 68. Key Raw Materials Price Trend
Figure 69. Manufacturing Cost Structure of High Potency APIs (HPAPI)
Figure 70. Manufacturing Process Analysis of High Potency APIs (HPAPI)
Figure 71. High Potency APIs (HPAPI) Industrial Chain Analysis
Figure 72. Channels of Distribution
Figure 73. Distributors Profiles
Figure 74. Porter's Five Forces Analysis
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed

---